Amritha Parthasarathy, DO
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 7 carriers
- Office
- 1
Offices
1 location
Hospitals listed: El Camino Health · Good Samaritan Hospital · Watsonville Community Hospital. That is not proof they admit you there this week.
Plans that list them
28 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Parthasarathy’s office at (408) 657-5620 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Watsonville Community HospitalWatsonville, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Watsonville Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.08) · 194 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.44 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.6 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.7 · 210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 74 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 604 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 1,963 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,942 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.66) · 232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.24 (0.54 to 3.95) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.09 (0.81 to 9.36) · 32 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.24) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 1.35) · 1,464 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.351 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 82 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.4 · 221 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.5 to 17.2) · 311 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 46 cases | No different | Jan 2024 – Dec 2024 |
What patients said (264 patients answered, 12% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$326,270
Medicare paid this office $326,270 for 405 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 107 | $84,971 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 157 | $65,036 | $105 |
| Long return visit (40+ min) | 182 | $59,838 | $165 |
| Botox | 12 | $24,350 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $18,416 | $151 |
See all 19 services
| Critical care, first 30-74 minutes | 107 | $84,971 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 157 | $65,036 | $105 |
| Long return visit (40+ min) | 182 | $59,838 | $165 |
| Botox | 12 | $24,350 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $18,416 | $151 |
| New patient visit (60+ min) | 79 | $15,617 | $198 |
| Critical care, each additional 30 minutes | 37 | $5,725 | $92 |
| Return visit (30+ min) | 38 | $5,603 | $119 |
| Evaluation of neuropsychological test, first hour | 46 | $5,601 | $119 |
| Ultrasound of within the brain blood flow for blood clots | 72 | $5,168 | $71 |
| Complete ultrasound of within the brain blood flow | 72 | $5,112 | $70 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 18 | $4,779 | $266 |
| Administration of psychological or neuropsychological test, first 30 minutes | 88 | $3,998 | $41 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 90 | $3,742 | $38 |
| Measurement of brain wave activity (eeg), awake and asleep | 50 | $3,015 | $60 |
| Measurement of brain wave activity (eeg), awake and drowsy | 43 | $2,570 | $51 |
| Short return visit (20+ min) | 24 | $2,183 | $84 |
| Measurement of brain wave activity (eeg), awake and drowsy | 21 | $1,082 | $52 |
| Measurement of brain wave activity (eeg), awake and asleep | 14 | $670 | $48 |
Who their Medicare patients are
405 Original Medicare patients in 2024. Average age 78 · Under 65 5% · 85 and older 22% · Women 55% · Also on Medicaid 19% · Health risk score 1.91. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 66% · Diabetes 44% · Coronary heart disease 44% · Chronic kidney disease 37% · Atrial fibrillation 35% · Dementia 35% · Depression 30% · Heart failure 28% · Cancer 19% · COPD 18%.
The office billed $603,885, Medicare allowed $414,275 and paid $326,270; for 7,283 services of 32 kinds; $24,350 of it was for drugs given in the office and $301,919 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 405 | 7,283 | 78 | 1.91 | $603,885 | $326,270 |
| 2023 | 155 | 1,046 | 78 | 1.75 | $123,325 | $71,218 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Critical care, first 30-74 minutes | 25 | $22,742 | $188 |
| Long return visit (40+ min) | 75 | $17,422 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $12,863 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,469 | $156 |
| New patient visit (60+ min) | 26 | $5,381 | $207 |
| Return visit (30+ min) | 12 | $1,590 | $122 |
Drugs they prescribed that Part D paid
$84,470
Pharmacies billed $84,470 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 615) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
545 generic and 70 brand-name prescriptions · $84,470 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rexulti | 31 | $44,743 | $1,443 |
| Rivastigmine | 46 | $12,782 | $278 |
| Lacosamide | 80 | $3,052 | $38 |
| Carbidopa-Levodopa | 47 | $1,676 | $36 |
| Memantine | 39 | $1,421 | $36 |
See all 12 drugs
| Rexulti | 31 | $44,743 | $1,443 |
| Rivastigmine | 46 | $12,782 | $278 |
| Lacosamide | 80 | $3,052 | $38 |
| Carbidopa-Levodopa | 47 | $1,676 | $36 |
| Memantine | 39 | $1,421 | $36 |
| Levetiracetam | 60 | $1,145 | $19 |
| Donepezil | 85 | $936 | $11 |
| Pregabalin | 40 | $719 | $18 |
| Clopidogrel | 37 | $437 | $12 |
| Gabapentin | 35 | $363 | $10 |
| Baclofen | 11 | $276 | $25 |
| Lamotrigine | 15 | $114 | $8 |
Year by year
| 2024 | 615 | 123 | 0% (0) | 11% | $84,470 |
| 2023 | 47 | 25 | 0% (0) | None | $3,903 |
| 2021 | 18 | None | 0% (0) | 0% | $122 |
| 2019 | 17 | None | 0% (0) | None | $1,335 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Levetiracetam | 15 | $752 | $50 |
Money from drug and device companies
$5,410 in 2025
| 2025 | 35 | 217 | None | $5,410 |
| 2024 | 26 | 131 | None | $3,054 |
| 2023 | 23 | 62 | None | $1,544 |
| 2020 | 3 | 3 | None | $206 |
| 2019 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alexion Pharmaceuticals | Ultomiris | $480 | 14 payments
|
| Catalyst Pharmaceuticals | Firdapse | $427 | 21 payments
|
| Lundbeck | Rexulti | $419 | 15 payments
|
| SK Life Science | None | $333 | 16 payments
|
| Ucb | Nayzilam | $329 | 9 payments
|
| Neurelis | Valtoco | $301 | 9 payments
|
See all 213 published payments
| CSL Behring | Meals · 2025-12-30 | Hizentra | $40 |
| ANI Pharmaceuticals | Meals · 2025-12-30 | Purified Cortrophin Gel | $26 |
| Biogen | Meals · 2025-12-20 | Tysabri | $19 |
| Ucb | Meals · 2025-12-20 | Rystiggo | $42 |
| Lundbeck | Meals · 2025-12-13 | Rexulti | $31 |
| Ucb | Meals · 2025-12-11 | Nayzilam | $43 |
| Amgen | Meals · 2025-12-11 | None | $21 |
| Neurelis | Meals · 2025-12-08 | Valtoco | $39 |
| ANI Pharmaceuticals | Meals · 2025-12-08 | Purified Cortrophin Gel | $10 |
| Argenx US | Meals · 2025-12-06 | Vyvgart Hytrulo | $25 |
| Merz Pharmaceuticals | Meals · 2025-12-05 | Inbrija | $14 |
| Tanabe Pharma America | Meals · 2025-12-04 | None | $18 |
| ANI Pharmaceuticals | Meals · 2025-12-03 | Purified Cortrophin Gel | $27 |
| Abbvie | Meals · 2025-12-02 | Qulipta | $7 |
| Genzyme | Meals · 2025-12-02 | None | $27 |
| Genentech USA | Meals · 2025-12-01 | Ocrevus Zunovo | $21 |
| Alexion Pharmaceuticals | Meals · 2025-11-27 | Ultomiris | $28 |
| Catalyst Pharmaceuticals | Meals · 2025-11-26 | Firdapse | $48 |
| Catalyst Pharmaceuticals | Meals · 2025-11-26 | Firdapse | $6 |
| SK Life Science | Meals · 2025-11-25 | None | $23 |
| SK Life Science | Meals · 2025-11-25 | None | $8 |
| Lilly USA | Meals · 2025-11-24 | None | $17 |
| Eisai | Meals · 2025-11-24 | Leqembi | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-21 | Wainua | $14 |
| Janssen Biotech | Meals · 2025-11-20 | None | $18 |
| Jazz Pharmaceuticals | Meals · 2025-11-20 | Epidiolex | $18 |
| Lundbeck | Meals · 2025-11-17 | Vyepti | $31 |
| Ucb | Meals · 2025-11-15 | Rystiggo | $25 |
| Celgene | Meals · 2025-11-12 | Zeposia | $14 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Kesimpta | $26 |
| Catalyst Pharmaceuticals | Meals · 2025-11-11 | Firdapse | $19 |
| Amgen | Meals · 2025-11-07 | None | $40 |
| Otsuka America Pharmaceutical | Meals · 2025-11-06 | Rexulti | $19 |
| Teva Pharmaceuticals USA | Meals · 2025-11-05 | Austedo Xr | $31 |
| Catalyst Pharmaceuticals | Meals · 2025-11-03 | Firdapse | $19 |
| Abbvie | Meals · 2025-10-29 | Botox | $24 |
| Abbvie | Meals · 2025-10-28 | Ubrelvy | $25 |
| ANI Pharmaceuticals | Meals · 2025-10-28 | Purified Cortrophin Gel | $33 |
| CSL Behring | Meals · 2025-10-25 | Hizentra | $33 |
| Lundbeck | Meals · 2025-10-23 | Rexulti | $15 |
| SK Life Science | Meals · 2025-10-23 | None | $28 |
| Lundbeck | Meals · 2025-10-22 | Vyepti | $29 |
| Abbvie | Meals · 2025-10-21 | Qulipta | $9 |
| Genzyme | Meals · 2025-10-20 | None | $24 |
| Neurelis | Meals · 2025-10-16 | Valtoco | $37 |
| Abbvie | Meals · 2025-10-15 | Botox | $28 |
| TG Therapeutics | Meals · 2025-10-15 | Briumvi | $34 |
| Eisai | Meals · 2025-10-15 | Leqembi | $12 |
| Genentech USA | Meals · 2025-10-14 | Ocrevus Zunovo | $19 |
| Ucb | Meals · 2025-10-14 | Nayzilam | $34 |
| Janssen Biotech | Meals · 2025-10-09 | None | $25 |
| Xeris Pharmaceuticals | Meals · 2025-10-07 | Keveyis | $22 |
| Catalyst Pharmaceuticals | Meals · 2025-10-07 | Firdapse | $16 |
| Lundbeck | Meals · 2025-10-04 | Rexulti | $34 |
| Catalyst Pharmaceuticals | Meals · 2025-10-02 | Firdapse | $11 |
| Catalyst Pharmaceuticals | Meals · 2025-10-02 | Firdapse | $21 |
| Teva Pharmaceuticals USA | Meals · 2025-10-01 | Austedo Xr | $32 |
| Neurelis | Meals · 2025-09-30 | Valtoco | $7 |
| Jazz Pharmaceuticals | Meals · 2025-09-30 | Epidiolex | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Kesimpta | $5 |
| Alexion Pharmaceuticals | Meals · 2025-09-26 | Ultomiris | $16 |
| ANI Pharmaceuticals | Meals · 2025-09-26 | Purified Cortrophin Gel | $27 |
| Merz Pharmaceuticals | Meals · 2025-09-25 | Inbrija | $45 |
| Eisai | Meals · 2025-09-22 | Leqembi | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-19 | Wainua | $15 |
| Eisai | Meals · 2025-09-19 | Leqembi | $17 |
| SK Life Science | Meals · 2025-09-19 | None | $20 |
| SK Life Science | Meals · 2025-09-19 | None | $3 |
| Alexion Pharmaceuticals | Meals · 2025-09-18 | Ultomiris | $98 |
| Ucb | Meals · 2025-09-18 | Nayzilam | $37 |
| Catalyst Pharmaceuticals | Meals · 2025-09-18 | Firdapse | $27 |
| Catalyst Pharmaceuticals | Meals · 2025-09-18 | Firdapse | $15 |
| Novartis Pharmaceuticals | Meals · 2025-09-17 | Kesimpta | $16 |
| Lilly USA | Meals · 2025-09-16 | Kisunla | $31 |
| Lundbeck | Meals · 2025-09-13 | Rexulti | $32 |
| Alexion Pharmaceuticals | Meals · 2025-09-11 | Ultomiris | $30 |
| Neurocrine BioSciences | Meals · 2025-09-11 | Ingrezza | $9 |
| Catalyst Pharmaceuticals | Meals · 2025-09-10 | Firdapse | $13 |
| Janssen Biotech | Meals · 2025-09-09 | None | $22 |
| Abbvie | Meals · 2025-09-05 | Botox | $32 |
| Genentech USA | Meals · 2025-09-04 | Ocrevus Zunovo | $21 |
| CSL Behring | Meals · 2025-09-04 | Hizentra | $35 |
| Neurocrine BioSciences | Meals · 2025-09-04 | Ingrezza | $13 |
| Abbvie | Meals · 2025-09-03 | Qulipta | $26 |
| Lundbeck | Meals · 2025-08-28 | Vyepti | $28 |
| Neurocrine BioSciences | Meals · 2025-08-22 | Ingrezza | $28 |
| ANI Pharmaceuticals | Meals · 2025-08-22 | Purified Cortrophin Gel | $34 |
| Ge Healthcare | Meals · 2025-08-21 | None | $34 |
| SK Life Science | Meals · 2025-08-21 | None | $31 |
| Novartis Pharmaceuticals | Meals · 2025-08-18 | Kesimpta | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-15 | Wainua | $16 |
| Neurelis | Meals · 2025-08-15 | Valtoco | $42 |
| TG Therapeutics | Meals · 2025-08-13 | Briumvi | $41 |
| Axsome Therapeutics | Meals · 2025-08-12 | Symbravo | $25 |
| Ucb | Meals · 2025-08-09 | Fintepla | $27 |
| Jazz Pharmaceuticals | Meals · 2025-08-06 | Epidiolex | $20 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Kesimpta | $16 |
| Janssen Biotech | Meals · 2025-08-01 | None | $36 |
| Eisai | Meals · 2025-07-31 | Leqembi | $30 |
| Alexion Pharmaceuticals | Meals · 2025-07-30 | Ultomiris | $34 |
| Ucb | Meals · 2025-07-25 | Nayzilam | $42 |
| SK Life Science | Meals · 2025-07-23 | None | $31 |
| SK Life Science | Meals · 2025-07-23 | None | $10 |
| Novartis Pharmaceuticals | Meals · 2025-07-22 | Kesimpta | $7 |
| ANI Pharmaceuticals | Meals · 2025-07-22 | Purified Cortrophin Gel | $25 |
| Catalyst Pharmaceuticals | Meals · 2025-07-22 | Firdapse | $3 |
| Catalyst Pharmaceuticals | Meals · 2025-07-22 | Firdapse | $11 |
| Lilly USA | Meals · 2025-07-18 | Kisunla | $31 |
| Neurocrine BioSciences | Meals · 2025-07-18 | Ingrezza | $17 |
| Alexion Pharmaceuticals | Meals · 2025-07-15 | Ultomiris | $14 |
| Neurocrine BioSciences | Meals · 2025-07-12 | Ingrezza | $33 |
| Lundbeck | Meals · 2025-07-11 | Vyepti | $35 |
| CSL Behring | Meals · 2025-07-09 | Hizentra | $36 |
| EMD Serono | Meals · 2025-07-09 | None | $35 |
| Neurelis | Meals · 2025-07-07 | Valtoco | $5 |
| Lundbeck | Meals · 2025-07-03 | Rexulti | $31 |
| Abbvie | Meals · 2025-07-02 | Botox | $4 |
| Abbvie | Meals · 2025-07-02 | Botox | $27 |
| Biogen | Meals · 2025-07-02 | Vumerity | $12 |
| Novartis Pharmaceuticals | Meals · 2025-07-01 | Kesimpta | $30 |
| Merz Pharmaceuticals | Meals · 2025-06-27 | Xeomin | $43 |
| Alexion Pharmaceuticals | Meals · 2025-06-25 | Ultomiris | $32 |
| Novartis Pharmaceuticals | Meals · 2025-06-23 | Kesimpta | $13 |
| Alexion Pharmaceuticals | Meals · 2025-06-20 | Ultomiris | $32 |
| Vanda Pharmaceuticals | Meals · 2025-06-20 | Ponvory | $25 |
| SK Life Science | Meals · 2025-06-19 | None | $16 |
| Octapharma USA | Meals · 2025-06-17 | Panzyga | $35 |
| Biogen | Meals · 2025-06-12 | Skyclarys | $28 |
| Catalyst Pharmaceuticals | Meals · 2025-06-10 | Firdapse | $51 |
| Catalyst Pharmaceuticals | Meals · 2025-06-10 | Firdapse | $4 |
| Abbvie | Meals · 2025-06-06 | Botox | $31 |
| SK Life Science | Meals · 2025-06-06 | None | $38 |
| Janssen Biotech | Meals · 2025-06-05 | None | $19 |
| Alexion Pharmaceuticals | Meals · 2025-06-04 | Ultomiris | $31 |
| Biogen | Meals · 2025-06-04 | Vumerity | $8 |
| Eisai | Meals · 2025-06-04 | Leqembi | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-29 | Kesimpta | $10 |
| Novartis Pharmaceuticals | Meals · 2025-05-22 | Kesimpta | $12 |
| Catalyst Pharmaceuticals | Meals · 2025-05-22 | Firdapse | $23 |
| Amneal Pharmaceuticals | Meals · 2025-05-21 | Rytary | $14 |
| Lundbeck | Meals · 2025-05-17 | Vyepti | $18 |
| Biogen | Meals · 2025-05-16 | Vumerity | $14 |
| Otsuka America Pharmaceutical | Meals · 2025-05-15 | Rexulti | $23 |
| Celgene | Meals · 2025-05-14 | Zeposia | $19 |
| Lilly USA | Meals · 2025-05-14 | Kisunla | $115 |
| Novartis Pharmaceuticals | Meals · 2025-05-14 | Kesimpta | $6 |
| CSL Behring | Meals · 2025-05-14 | Hizentra | $43 |
| Biogen | Meals · 2025-05-13 | Skyclarys | $20 |
| Lundbeck | Meals · 2025-05-10 | Rexulti | $26 |
| Neurelis | Meals · 2025-05-08 | Valtoco | $45 |
| CSL Behring | Education · 2025-05-06 | Hizentra | $12 |
| Neurocrine BioSciences | Meals · 2025-05-02 | Ingrezza | $39 |
| Alexion Pharmaceuticals | Meals · 2025-04-30 | Ultomiris | $35 |
| Biogen | Meals · 2025-04-28 | Vumerity | $9 |
| Novartis Pharmaceuticals | Meals · 2025-04-23 | Kesimpta | $32 |
| Biogen | Meals · 2025-04-17 | Vumerity | $27 |
| Eisai | Meals · 2025-04-16 | Leqembi | $29 |
| SK Life Science | Meals · 2025-04-16 | None | $17 |
| Neurocrine BioSciences | Meals · 2025-04-12 | Ingrezza | $25 |
| Biogen | Meals · 2025-04-11 | Skyclarys | $29 |
| SK Life Science | Meals · 2025-04-08 | None | $27 |
| Alexion Pharmaceuticals | Meals · 2025-04-04 | Ultomiris | $26 |
| Novartis Pharmaceuticals | Meals · 2025-04-03 | Kesimpta | $9 |
| Vanda Pharmaceuticals | Meals · 2025-04-01 | Ponvory | $33 |
| Lundbeck | Meals · 2025-03-28 | Vyepti | $28 |
| Novartis Pharmaceuticals | Meals · 2025-03-26 | Kesimpta | $17 |
| Neurelis | Meals · 2025-03-26 | Valtoco | $47 |
| Amneal Pharmaceuticals | Meals · 2025-03-26 | Rytary | $28 |
| Catalyst Pharmaceuticals | Meals · 2025-03-24 | Fycompa | $36 |
| Catalyst Pharmaceuticals | Meals · 2025-03-24 | Fycompa | $2 |
| Lundbeck | Meals · 2025-03-22 | Rexulti | $29 |
| SK Life Science | Meals · 2025-03-20 | None | $24 |
| Celgene | Meals · 2025-03-19 | Zeposia | $20 |
| Lilly USA | Meals · 2025-03-19 | Kisunla | $18 |
| Novartis Pharmaceuticals | Meals · 2025-03-19 | Kesimpta | $13 |
| Abbvie | Meals · 2025-03-19 | Qulipta | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-03-19 | Rexulti | $30 |
| Harmony Biosciences | Meals · 2025-03-14 | Wakix | $33 |
| Eisai | Meals · 2025-03-14 | Leqembi | $23 |
| Biogen | Meals · 2025-03-13 | Skyclarys | $30 |
| Novartis Pharmaceuticals | Meals · 2025-03-11 | Kesimpta | $15 |
| Catalyst Pharmaceuticals | Meals · 2025-03-11 | Fycompa | $43 |
| Biogen | Meals · 2025-03-05 | Tysabri | $11 |
| Genentech USA | Meals · 2025-03-05 | Ocrevus Zunovo | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-03-05 | Rexulti | $124 |
| ANI Pharmaceuticals | Meals · 2025-03-05 | Purified Cortrophin Gel | $32 |
| Ucb | Meals · 2025-03-01 | Briviact | $33 |
| Biogen | Meals · 2025-02-14 | Vumerity | $10 |
| Otsuka America Pharmaceutical | Meals · 2025-02-14 | Rexulti | $14 |
| Eisai | Meals · 2025-02-13 | Leqembi | $23 |
| Lilly USA | Meals · 2025-02-12 | Kisunla | $26 |
| Neurelis | Meals · 2025-02-12 | Valtoco | $43 |
| Lilly USA | Education · 2025-02-11 | None | $1 |
| Lundbeck | Meals · 2025-02-07 | Rexulti | $27 |
| Biogen | Meals · 2025-02-06 | Skyclarys | $15 |
| Catalyst Pharmaceuticals | Meals · 2025-02-06 | Fycompa | $9 |
| Catalyst Pharmaceuticals | Meals · 2025-02-06 | Fycompa | $13 |
| SK Life Science | Meals · 2025-02-05 | None | $35 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Kesimpta | $26 |
| Alexion Pharmaceuticals | Meals · 2025-01-31 | Ultomiris | $34 |
| Neurocrine BioSciences | Meals · 2025-01-30 | Ingrezza | $30 |
| Neurocrine BioSciences | Meals · 2025-01-30 | Ingrezza | $11 |
| Alexion Pharmaceuticals | Meals · 2025-01-29 | Ultomiris | $38 |
| SK Life Science | Meals · 2025-01-28 | None | $20 |
| SK Life Science | Meals · 2025-01-28 | None | $2 |
| Lilly USA | Meals · 2025-01-23 | Kisunla | $24 |
| Neurelis | Meals · 2025-01-21 | Valtoco | $36 |
| Catalyst Pharmaceuticals | Meals · 2025-01-16 | Fycompa | $35 |
| Genentech USA | Meals · 2025-01-15 | Ocrevus | $26 |
| Lundbeck | Meals · 2025-01-15 | Vyepti | $27 |
| Ucb | Meals · 2025-01-10 | Briviact | $44 |
| Alexion Pharmaceuticals | Meals · 2025-01-08 | Ultomiris | $33 |
| ANI Pharmaceuticals | Meals · 2025-01-08 | Purified Cortrophin Gel | $30 |
See earlier years (2024, 2023, 2020, 2019)
2024: $3,054
| Neurelis | Valtoco | $328 | 14 payments
|
| Novartis Pharmaceuticals | Kesimpta | $327 | 10 payments
|
| Lundbeck | Vyepti | $275 | 13 payments
|
| SK Life Science | Xcopri | $249 | 10 payments
|
| Catalyst Pharmaceuticals | Fycompa | $212 | 14 payments
|
| Ucb | Briviact | $189 | 7 payments
|
| Abbvie | Ubrelvy | $168 | 9 payments
|
| EMD Serono | None | $159 | 5 payments
|
| Alexion Pharmaceuticals | Ultomiris | $152 | 6 payments
|
| Biogen | Tysabri | $140 | 7 payments
|
| Eisai | Leqembi | $134 | 6 payments
|
| Merz Pharmaceuticals | Xeomin | $81 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $81 | 3 payments
|
| Lilly USA | Amyvid | $69 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $63 | 3 payments
|
| Celgene | Zeposia | $57 | 2 payments
|
| Kyowa Kirin | Nourianz | $49 | 2 payments
|
| Harmony Biosciences | Wakix | $48 | 2 payments
|
| Banner Life Sciences | Bafiertam | $47 | 2 payments
|
| Sumitomo Pharma America | Aptiom | $47 | 2 payments
|
| Pfizer | Nurtec Odt | $45 | 2 payments
|
| Octapharma USA | Panzyga | $41 | 2 payments
|
| Acorda Therapeutics | Inbrija | $40 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Wainua | $18 | 1 payment
|
| Boston Scientific | Watchman Flx | $17 | 1 payment
|
| Genentech USA | Ocrevus | $16 | 1 payment
|
2023: $1,544
| Abbvie | Qulipta | $302 | 9 payments
|
| Biogen | Tysabri | $275 | 11 payments
|
| SK Life Science | None | $107 | 4 payments
|
| Ucb | Briviact | $93 | 4 payments
|
| Sumitomo Pharma America | Aptiom | $85 | 3 payments
|
| Genentech USA | Enspryng | $76 | 3 payments
|
| Acorda Therapeutics | Inbrija | $76 | 4 payments
|
| Argenx US | Vyvgart | $65 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $59 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $57 | 3 payments
|
| Lundbeck | Vyepti | $55 | 2 payments
|
| Neurelis | Valtoco | $54 | 2 payments
|
| Catalyst Pharmaceuticals | Fycompa | $41 | 3 payments
|
| Neurocrine Biosciences | Ongentys | $29 | 1 payment
|
| Lilly USA | Amyvid | $26 | 2 payments
|
| Harmony Biosciences | Wakix | $24 | 1 payment
|
| Pfizer | Nurtec Odt | $20 | 1 payment
|
| Octapharma USA | Panzyga | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $17 | 1 payment
|
| EMD Serono | Mavenclad | $17 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $16 | 1 payment
|
| Scilex Pharmaceuticals | Elyxyb | $16 | 1 payment
|
| Celgene | Zeposia | $15 | 1 payment
|
2020: $206
| Genentech USA | Activase | $150 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $40 | 1 payment
|
| Grifols USA | Gamunex-C | $16 | 1 payment
|
2019: $22
| Grifols USA | Gamunex-C | $22 | 1 payment
|
Professional record
- NPI
- 1174010771
- Licence
- CA 20A17912
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Hospitalist (208M00000X); Student in a training program (390200000X)
- Mailing address
- 2512 Samaritan Ct Ste S, San Jose, CA, 95124
- NPI first listed
- 2018-04-18
- NPI last updated
- 2026-07-20
- NPI record certified
- 2026-07-20
This is when the NPI record was last certified, not a medical board exam.